This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Loqtorzi industry.
What is the current market size of the loqtorzi industry, and what growth rate is it expected to achieve?
The loqtorzi market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to an increase in the number of clinics, growing demand for effective treatment options, increasing smoking prevalence, rising health care investments, and growing adoption of immunotherapy.
The loqtorzi market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to the rising burden of the cancer disease, growing awareness towards diagnosis and treatment, rising prevalence of nasopharyngeal cancer cases, increasing adoption of combination therapies, and increasing focus on early detection and prevention. Major trends in the forecast period include advancements in diagnosis, innovations in treatment modalities, innovative drug formulations, advancements in the radiation therapy techniques, and advancements in precision medicine.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20148&type=smp
What are the major drivers contributing to the growth of the loqtorzi market?
The rise in the prevalence of nasopharyngeal carcinoma is expected to propel the growth of the loqtorzi market going forward. Nasopharyngeal carcinoma is a type of cancer that affects the nasopharynx and is strongly linked to Epstein-Barr virus infection, with early diagnosis playing a key role in treatment outcomes. The rise in prevalence of nasopharyngeal carcinoma can be attributed to factors such as increased exposure to the Epstein-Barr virus, genetic predisposition, environmental factors such as tobacco and alcohol use, and dietary habits, particularly the consumption of salted and preserved food. Loqtorzi (toripalimab) helps nasopharyngeal carcinoma (NPC) patients by enhancing the immune system’s ability to attack cancer cells through the inhibition of the PD-1 pathway, offering a novel treatment option for those with recurrent or metastatic NPC, either in combination with chemotherapy or as a monotherapy after disease progression. For instance, in 2022, the World Cancer Research Fund, a US-based cancer charity, reported that more than 120,434 new cases of nasopharyngeal cancer (NPC) were diagnosed worldwide. Therefore, the rise in the prevalence of nasopharyngeal carcinoma is driving the growth of the loqtorzi market.
What are the major market segments driving the growth of the loqtorzi industry?
The loqtorzi market covered in this report is segmented –
1) By Formulation: Injectable Formulation (intravenous), Lyophilized Powder For Reconstitution
2) By Indication: Treatment Of Small Cell Lung Cancer (SCLC), Treatment Of Other Solid Tumors
3) By Patient Demographics: Adult Patients, Geriatric Patients, Pediatric Patients
4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Oncology Clinics, Specialty Pharmacies, Research Institutions
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/loqtorzi-global-market-report
What are the key trends shaping the loqtorzi market in the forecast period?
They key trend in the loqtorzi market is focusing on developing biosimilars to expand its portfolio and offer cost-effective treatment alternatives to biologic therapies. Biosimilars are biologic products that are highly similar to an approved reference product, with no clinically meaningful differences in safety or effectiveness. They provide an affordable alternative to expensive biologic drugs once the original product’s patent expires. For instance, in November 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, launched a biosimilar of Coherus BioSciences’ (CHRS) Loqtorzi (toripalimab) in India under the brand name Zytorvi. The drug is indicated for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a rare form of cancer. Loqtorzi was FDA-approved in October 2023 for first-line treatment of RM-NPC in combination with cisplatin and gemcitabine and as a monotherapy for patients with disease progression after platinum-based chemotherapy. It is the only FDA-approved immuno-oncology drug for this indication.
Who are the key market players contributing to the growth of the loqtorzi industry?
Major companies operating in the loqtorzi market include Coherus BioSciences Inc.; Shanghai Junshi Biosciences Co. Ltd.
Which regions are leading the growth of the loqtorzi market globally?
North America was the largest region in the loqtorzi market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the loqtorzi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
How Can Companies Use The Loqtorzi Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20148
Need Customized Data On Loqtorzi Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=20148&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
